Novo Nordisk A/S (NYSE:NVO) Shares Sold by Pinnacle Bancorp Inc.

Pinnacle Bancorp Inc. lowered its stake in Novo Nordisk A/S (NYSE:NVO) by 37.0% in the first quarter, Holdings Channel.com reports. The institutional investor owned 942 shares of the company’s stock after selling 554 shares during the quarter. Pinnacle Bancorp Inc.’s holdings in Novo Nordisk A/S were worth $65,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. GQG Partners LLC grew its position in Novo Nordisk A/S by 74.7% in the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company’s stock valued at $1,117,790,000 after acquiring an additional 5,556,460 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Novo Nordisk A/S during the 4th quarter valued at $404,910,000. Loomis Sayles & Co. L P increased its stake in Novo Nordisk A/S by 34.2% during the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company’s stock worth $995,397,000 after buying an additional 2,947,771 shares during the period. Nuveen Asset Management LLC lifted its holdings in Novo Nordisk A/S by 73.2% in the 4th quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company’s stock worth $537,189,000 after buying an additional 2,639,693 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new position in Novo Nordisk A/S in the 4th quarter worth $158,657,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on NVO shares. Dbs Bank downgraded Novo Nordisk A/S to a “sell” rating in a research note on Friday, April 25th. BNP Paribas assumed coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They set an “underperform” rating on the stock. Stifel Nicolaus cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Guggenheim downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 17th. Finally, Hsbc Global Res raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, April 28th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $112.00.

Novo Nordisk A/S Trading Down 4.8%

Shares of NYSE NVO opened at $67.37 on Thursday. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70. The stock’s 50 day moving average price is $68.70 and its two-hundred day moving average price is $77.86. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $145.99. The stock has a market capitalization of $300.81 billion, a P/E ratio of 19.93, a PEG ratio of 1.26 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The business had revenue of $11.87 billion for the quarter. On average, analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.